Grzegorz Słonka
Medical University of Silesia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Grzegorz Słonka.
International Journal of Cardiology | 2013
Przemysław Trzeciak; Marek Gierlotka; Mariusz Gąsior; Andrzej Lekston; Krzysztof Wilczek; Grzegorz Słonka; Zbigniew Kalarus; Marian Zembala; Bartosz Hudzik; Lech Poloński
BACKGROUND Mortality of patients with ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock (CS) on admission remains high despite invasive treatment. The aim of this analysis was to assess the relationship between the infarct-related artery (IRA) and the early and 12-month outcomes of patients with STEMI and CS treated by percutaneous coronary intervention (PCI). METHODS Two thousand ninety patients with STEMI and CS registered in the prospective Polish Registry of Acute Coronary Syndromes from October 2003 to November 2009 were included. RESULTS The in-hospital mortality in the left main (LM), left anterior descending artery (LAD), circumflex artery (Cx), and right coronary artery (RCA) groups was 64.7%, 41.0%, 36.0%, and 30.8%, respectively, with p<0.0001. The 12-month mortality in the LM, LAD, Cx, and RCA groups was 77.7%, 58.2%, 55.1%, and 45.0%, respectively, with p<0.0001. After multivariate adjustment, LM as the IRA was significantly associated with higher 12-month mortality (hazard ratio=1.71, 95% confidence interval=1.28-2.27, p=0.0002). CONCLUSIONS In-hospital and long-term mortality of patients with STEMI and CS treated by PCI are significantly correlated to the IRA, being highest for LM and lowest for RCA.
Coronary Artery Disease | 2010
Andrzej Lekston; Grzegorz Słonka; Mariusz Gasior; Damian Pres; Marek Gierlotka; Tadeusz Zębik; Jarosław Wasilewski; Jan Głowacki; Lech Poloński
ObjectivesCardiogenic shock (CS) still remains one of the most important factors affecting the mortality rate of patients with ST segment elevation myocardial infarction (STEMI). However, the data with follow-up longer than 1 year are limited. The aim of this study was to evaluate the early and long-term treatment results of patients with STEMI, complicated or not by CS, who underwent percutaneus coronary interventions. MethodsA retrospective registry included data of all patients with STEMI admitted to our centre from January 1999 to December 2001. ResultsOne thousand three hundred and eighty-five patients with STEMI were hospitalized and 1237 of them were treated with immediate percutaneus coronary interventions. Among this subpopulation, 117 (9.5%) patients were with STEMI complicated with CS on admission (group I) and 1120 (90.5%) patients were with STEMI without complications from CS on admission (group II). The groups differed significantly with regard to baseline clinical characteristics, angiographic picture, and in-hospital course. A total of 38.5% of patients with myocardial infarction complicated by CS and 2.5% of patients without shock (P<0.001) died during hospitalization. At the 5-year follow-up, 58.1% of group I patients and 14.8% of group II patients (P<0.001) died. A significant difference in the 5-year mortality rate was also observed in patients who survived the in-hospital period (31.9 vs. 12.6%; P<0.001). ConclusionCS continues to be closely connected with a very high mortality rate both in the hospital and in the long-term, also among patients who survived the in-hospital period.
Kardiologia Polska | 2014
Mariusz Gąsior; Pyka Ł; Jarosław Gorol; Michał Hawranek; Mateusz Tajstra; Grzegorz Słonka; Anna Kurek; Krajewski A; Piotr Rozentryt; Marek Gierlotka; Andrzej Lekston; Michał Zembala; Lech Poloński
BACKGROUND AND AIM Heart failure (HF) has become a global health problem and is a significant burden for health-care systems worldwide. It is reported as the reason for 1-4% of all hospital admissions in developed countries. The prognosis in HF remains unfavourable. Having at our disposal a large group of patients with systolic HF at a high-volume reference cardiovascular centre with the possibility to implement complete diagnostics and therapy we decided to analyse the clinical data, administered therapies, and prognosis in HF patients. METHODS The COMMIT-HF is a single-centre observational study that is underway in the Third Chair and Department of Cardiology of the Silesian Centre for Heart Diseases in Zabrze. The study population is a cohort of adult HF patients with left ventricular ejection fraction (LVEF) ≤ 35%. Patients with acute coronary syndromes are excluded from the analysis. Complete patient demographics: medical history, hospitalisation data (diagnostic and therapeutic), and in-hospital results are collected. Twelve-month follow-up is based on the information acquired from the national health-care provider. RESULTS As of 31 December 2013 a group of 1798 patients have been enrolled (mean age 60.9 ± 12.8 years, 20.3% of subjects female, mean LVEF 26.06 ± 6.09, ischaemic aetiology 64.5%, atrial fibrillation 33.2%, diabetes mellitus 41.2%, chronic kidney disease stage ≥ III 29%). A significant proportion of patients underwent invasive procedures (ICD/CRT-D implantation 61.1%, coronary angiography 56.2%, PCI 19.6%, CABG 5.1%, heart transplantation qualification 5.5%, IABP 2.5%). All-cause 12-month morality was 12.5%. HF-related rehospitalisation rate was 28.9%. CONCLUSIONS The COMMIT-HF study will provide valuable information on the HF patient population. Initial analyses show that in this difficult patient population satisfactory long-term results can be achieved.
Kardiologia Polska | 2017
Paweł Nadziakiewicz; Michał Zembala; Grzegorz Słonka; Wojciech Balak
1Department of Cardiac Anaesthesia and Intensive Care, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland 2Department of Cardiac Surgery and Transplantation, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland 3Department of Cardiology, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland 42nd Chair and Clinic of Cardiology, Nicolaus Copernicus University in Torun, Collegium Medicum, Bydgoszcz, Poland
Kardiologia Polska | 2007
Grzegorz Słonka; Gasior M; Andrzej Lekston; Marek Gierlotka; Hawranek M; Tajstra M; Lech Poloński
Kardiologia Polska | 2012
Mariusz Gąsior; Damian Pres; Marek Gierlotka; Michał Hawranek; Grzegorz Słonka; Andrzej Lekston; Pawel Buszman; Zbigniew Kalarus; Marian Zembala; Lech Poloński
Kardiologia Polska | 2010
Damian Pres; Gasior M; Andrzej Lekston; Marek Gierlotka; Hawranek M; Tajstra M; Piotr Buchta; Grzegorz Słonka; Lech Poloński
Polish archives of internal medicine | 2017
Mateusz Ostręga; Marek Gierlotka; Grzegorz Słonka; Paweł Nadziakiewicz; Mariusz Gąsior
Kardiologia Polska | 2007
Mateusz Tajstra; Mariusz Gąsior; Andrzej Lekston; Krzysztof Wilczek; Michał Hawranek; Marek Gierlotka; Grzegorz Słonka; Tadeusz Zębik; Lech Poloński
Kardiologia Inwazyjna | 2017
Grzegorz Słonka; Michał Hawranek; Łukasz Siedlecki; Tomasz Hrapkowicz; Damian Pres; Mariusz Gąsior; Marek Gierlotka